Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fractional CO₂ Laser With and Without Intradermal Botulinum Toxin A for Inflammatory Facial Acne Vulgaris
NCT07919886Phase 3Not yet recruiting
- Sponsor
- Cairo University
- Start
- Nov 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of botulinum toxin type A in acne vulgaris (2 arms), sponsored by Cairo University. Primary endpoints: Percentage change in lesion count at 24 weeks and Global Acne Grading System at 24 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT07919886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07919886.